| Integrative clinical genomics of advanced prostate cancer D Robinson, EM Van Allen, YM Wu, N Schultz, RJ Lonigro, JM Mosquera, ... Cell 161 (5), 1215-1228, 2015 | 3618 | 2015 |
| DNA-repair defects and olaparib in metastatic prostate cancer J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ... New England Journal of Medicine 373 (18), 1697-1708, 2015 | 2259 | 2015 |
| Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition J Goodall, J Mateo, W Yuan, H Mossop, N Porta, S Miranda, ... Cancer discovery 7 (9), 1006-1017, 2017 | 387 | 2017 |
| PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate R Ferraldeschi, DN Rodrigues, R Riisnaes, S Miranda, I Figueiredo, ... European urology 67 (4), 795-802, 2015 | 269 | 2015 |
| Genomics of lethal prostate cancer at diagnosis and castration resistance J Mateo, G Seed, C Bertan, P Rescigno, D Dolling, I Figueiredo, ... The Journal of clinical investigation 130 (4), 1743-1751, 2020 | 227 | 2020 |
| Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration JS Frenel, S Carreira, J Goodall, D Roda, R Perez-Lopez, N Tunariu, ... Clinical Cancer Research 21 (20), 4586-4596, 2015 | 201 | 2015 |
| Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors TA Yap, B O’Carrigan, MS Penney, JS Lim, JS Brown, ... Journal of Clinical Oncology 38 (27), 3195, 2020 | 182 | 2020 |
| Sequencing of agents in castration-resistant prostate cancer D Lorente, J Mateo, R Perez-Lopez, JS de Bono, G Attard The lancet oncology 16 (6), e279-e292, 2015 | 181 | 2015 |
| Managing nonmetastatic castration-resistant prostate cancer J Mateo, K Fizazi, S Gillessen, A Heidenreich, R Perez-Lopez, WJG Oyen, ... European urology 75 (2), 285-293, 2019 | 158 | 2019 |
| SPOP-mutated/CHD1-deleted lethal prostate cancer and abiraterone sensitivity G Boysen, DN Rodrigues, P Rescigno, G Seed, D Dolling, R Riisnaes, ... Clinical cancer research 24 (22), 5585-5593, 2018 | 141 | 2018 |
| Clinical outcome of prostate cancer patients with germline DNA repair mutations: retrospective analysis from an international study J Mateo, HH Cheng, H Beltran, D Dolling, W Xu, CC Pritchard, H Mossop, ... European urology 73 (5), 687-693, 2018 | 118 | 2018 |
| Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis M Ligero, O Jordi-Ollero, K Bernatowicz, A Garcia-Ruiz, ... European radiology 31, 1460-1470, 2021 | 106 | 2021 |
| Diffusion-weighted imaging as a treatment response biomarker for evaluating bone metastases in prostate cancer: a pilot study R Perez-Lopez, J Mateo, H Mossop, MD Blackledge, DJ Collins, M Rata, ... Radiology 283 (1), 168-177, 2017 | 104 | 2017 |
| Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 criteria I Matos, J Martin-Liberal, A García-Ruiz, C Hierro, M Ochoa de Olza, ... Clinical Cancer Research 26 (8), 1846-1855, 2020 | 87 | 2020 |
| Prostate-specific antigen decline after 4 weeks of treatment with abiraterone acetate and overall survival in patients with metastatic castration-resistant prostate cancer P Rescigno, D Lorente, D Bianchini, R Ferraldeschi, MP Kolinsky, ... European urology 70 (5), 724-731, 2016 | 87 | 2016 |
| A CT-based radiomics signature is associated with response to immune checkpoint inhibitors in advanced solid tumors M Ligero, A Garcia-Ruiz, C Viaplana, G Villacampa, MV Raciti, J Landa, ... Radiology 299 (1), 109-119, 2021 | 65 | 2021 |
| Volume of bone metastasis assessed with whole-body diffusion-weighted imaging is associated with overall survival in metastatic castration-resistant prostate cancer R Perez-Lopez, D Lorente, MD Blackledge, DJ Collins, J Mateo, ... Radiology 280 (1), 151-160, 2016 | 63 | 2016 |
| Imaging diagnosis and follow-up of advanced prostate cancer: clinical perspectives and state of the art R Perez-Lopez, N Tunariu, AR Padhani, WJG Oyen, S Fanti, HA Vargas, ... Radiology 292 (2), 273-286, 2019 | 56 | 2019 |
| RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer E Elez, J Ros, J Fernández, G Villacampa, AB Moreno-Cárdenas, ... Nature medicine 28 (10), 2162-2170, 2022 | 50 | 2022 |
| Multiparametric magnetic resonance imaging of prostate cancer bone disease: correlation with bone biopsy histological and molecular features R Perez-Lopez, DN Rodrigues, I Figueiredo, J Mateo, DJ Collins, DM Koh, ... Investigative radiology 53 (2), 96, 2018 | 44 | 2018 |
